ENANTA PHARMACEUTICALS, INC (ENTA) Return on equity 2017–2025
ENANTA PHARMACEUTICALS, INC (ENTA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-179.3%FY2025 · since FY2017: 7.2% → -179.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -179.3% | -75.4 pp |
| FY2024 | -103.9% | -47.7 pp |
| FY2023 | -56.2% | -31.6 pp |
| FY2022 | -24.6% | -15.5 pp |
| FY2021 | -9.1% | -19.2 pp |
| FY2020 | 10.2% | -5.4 pp |
| FY2019 | 15.6% | +11.1 pp |
| FY2018 | 4.5% | -2.7 pp |
| FY2017 | 7.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ENTA financial trends
ENTA RevenueENTA Net incomeENTA Net marginENTA Gross profitENTA Gross marginENTA Operating incomeENTA Operating marginENTA Operating cash flowENTA Free cash flowENTA Capital expendituresENTA Stock buybacksENTA Dividends paidENTA Total assetsENTA Total liabilitiesENTA Shareholders’ equityENTA overview →